Although, a VEGF/VEGFR-targeted strategy has been used in the patients with CRC with or without RAS mutations, patients with left-sided mCRC and right-sided mCRC with KRAS/NRAS/BRAF mutations should be considered for a VEGF/VEGFR-targeted drug containing chemotherapy regimens. The gene discussed is KRAS; the disease is colorectal carcinoma.